WHO Advises Against Use of Hydrocortisone and Corticosteroids for COVID-19 Patients

Worldwide the COVID-19 (coronavirus) outbreak has created major challenges for clinicians. Lack of proven pharmacological therapies for the treatment of COVID-19 has resulted in increased mortality rates. Corticosteroids were extensively used during outbreaks of Severe Acute Respiratory Syndrome (SARS)-CoV as well as the Middle East Respiratory Syndrome (MERS)-CoV. This technique has led to the application of corticosteroids for COVID-19 patient, in combination with other therapeutic agents. However, the WHO (World Health Organization) advises against the use of corticosteroids due to the lack of reliable clinical evidence. Thus, companies in the hydrocortisone market are unable to capitalize on the needs of COVID-19 patients when actually there is an unprecedented demand for drugs that fight off the infection.

Companies in the hydrocortisone market are increasing efforts to identify the harm and benefits caused by corticosteroids for the treatment of coronavirus.

hydrocortisone market infographic

To know the scope of our report Get a Sample on Hydrocortisone Market 

Home Treatment for Children Sparks Innovations in Intramuscular Preparations of Hydrocortisone 

Several children are prone to the risks of adrenal insufficiency, since they are unable to mount an endogenous cortisol response to stress. Such children usually receive treatment at home by seeking telephone advices from doctors. Thus, companies in the hydrocortisone market should tap into opportunities in child care to broaden their revenue streams. As such, adrenocortical insufficiency is one of the key medical indications that demand hydrocortisone drugs and the market is predicted to reach a value of ~US$ 2 Bn by the end of 2028.

Get a glimpse of the in-depth analysis through our Report Brochure

Many children are administered oral corticosteroids such as hydrocortisone, dexamethasone, and prednisolone on a daily basis since adrenocortical insufficiency is potentially life threatening. Problems arising from such medical conditions have fueled the demand for steroid medicines that are generally administered intramuscularly or intravenously, depending on the severity of the clinical situation. Companies in the hydrocortisone market are increasing the availability of hydrocortisone sodium succinate and hydrocortisone sodium phosphate for treatment of children that require extra steroids.

Dual Release Hydrocortisone Dosage Boosts Metabolism in Hypoadrenalism Patients

Companies in the hydrocortisone market are introducing medicines that do not require a prescription. For instance, in May 2019, Aflofarm— a supplier of Over the Counter drugs (OTC) and medical devices, announced the launch of Maxicortan, a medicine with double dose of hydrocortisone that can be applied locally on skin inflammations and caters to individuals with atopic dermatitis. As such, dermatitis is one the key medical indications that is creating incremental opportunities for companies in the hydrocortisone market. Therapeutic indications such as allergic contact dermatitis, urticarial, and skin reactions after insect bites are also creating revenue streams for pharmaceutical companies.

On the other hand, dual release hydrocortisone is becoming popular as a metabolism improver agent for patients with adrenal insufficiency. Healthcare professionals are recommending once daily dual release hydrocortisone to provide adequate cortisol exposure time. Since conventional GC (Glucocorticoid) therapy is associated with increased morbidity and mortality, gradual increase in the dosage of dual release hydrocortisone has helped to improve hypoadrenalism patient quality of life.

Need for Clinical Trails Validate Lowest Doses of Hydrocortisone for Shock Reversal

Septic shock is a life-threatening condition that has led to high mortality rates. Hence, clinicians recommend corticosteroids such as hydrocortisone to reduce the severity of trauma caused in patients. As such, hydrocortisone medicines are subject to intensive investigation in several clinical trials. Currently, low-dose hydrocortisone is being highly publicized for shock reversal, resulting in lesser adverse events among patients. This has led to better clinical outcomes as compared to placebo.

Although hydrocortisone aids in faster resolution of shock than placebo, the optimal dosage for hemodynamic support during septic shock is still unclear. This explains why the hydrocortisone market is progressing at a modest CAGR of ~4% during the forecast period, due to lack of reliable clinical evidence. However, growing awareness about the lowest initial dose of hydrocortisone in adults is helping to revive growth for the hydrocortisone market. This awareness is increasing as a result of the rise in the number of randomized clinical trials.

hydrocortisone market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

The evidences of harm and benefits of corticosteroids have gained prime importance for companies in the hydrocortisone market amidst the coronavirus outbreak. Hydrocortisone medicines are being increasingly used as adjunctive treatment to septic shock.

The glucocorticoid treatment is being combined with hydrocortisone or cortisone acetate for the treatment of adrenal insufficiency (AI) patients. However, this combination treatment has led to overexposure toward GCs, resulting in metabolic dysfunction. Hence, companies should increase awareness of once daily dual release hydrocortisone dose that gradually increases dosage content among AI patients. Companies should gain efficacy in no prescription medicines to increase product uptake among individuals with therapeutic indications such as dermatitis.

Hydrocortisone Market: Overview

  • According to Transparency Market Research’s latest report on the global hydrocortisone market for the historical period 2018–2019 and forecast period 2020–2028, rise in cases of adrenocortical insufficiency and increase in investment in research & development are projected to drive the global hydrocortisone market during the forecast period
  • According to the report, the global hydrocortisone market was valued at US$ 1.25 Bn in 2019 and is anticipated to expand at a CAGR of ~4% from 2020 to 2028

Rise in Cases of Adrenocortical Insufficiency: Key Drivers

  • Adrenal insufficiency is a serious pathologic condition characterized by decreased production or action of glucocorticoids and/or mineralocorticoids and adrenal androgens
  • Prevalence of chronic primary adrenal insufficiency in Europe has been doubled from 40 to 70 cases per million population in the 1960s to 93 to 144 cases per million population by the end of 2017
  • The incidence of the most frequent cause in adults, auto-immune adrenal insufficiency, is estimated at 4.4 to 6.0 per million each year in Europe
  • As per data published in the Military Health System article in 2017, incidence rate of adrenal deficiency from 2014 to 2017 was around 6 per 100,000 per year. This incidence was approximately 5 per 100,000 per year during the time period of 2010 to 2013.
  • Symptoms of ACTH deficiency most often occur in adults, but the disorder may also be diagnosed in infancy
  • However, cortisone or glucocorticoid-induced secondary adrenal insufficiency is the most frequent cause of ACTH insufficiency. The prevalence is almost twice as high as that of primary adrenal deficiency cases, which is around 150 to 280 per million in 2017 and is more common in women than men.
  • Thus, rise in prevalence and incidence of ACTH deficiency cases boost the hydrocortisone market

Increasing Prevalence of Several Acute and Chronic Disorders Worldwide Boost Market Growth

  • The number of patients affected with chronic diseases is rising consistently across the world. The root cause of a number of these diseases can be traced to a lack of healthy lifestyle and dietary habits that leads to deficiency of various essential vitamins and minerals. Rise in number of these diseases propels the demand for vitamins and other nutrient supplements.
  • Cardiovascular and respiratory diseases have affected a large number of individuals, globally, and are the leading cause of death among the global population. Cardiovascular diseases cause majority of deaths worldwide. According to the World Health Organization (WHO), an estimated 17.9 million people die each year due to cardiovascular disorders (CVD).
  • Increase in incidence of chronic diseases of liver, heart, kidneys, and pancreas; and blood disorders, have augmented the demand for glucocorticoids such as hydrocortisone
  • Therefore, a rise in the incidence of chronic diseases and an increase in the geriatric population across the globe is fueling the hydrocortisone market

Side Effects Associated with Hydrocortisone Use to Hamper Market

  • Glucocorticoids may sound like miracle drugs, but they do have side effects. Some of them are critical and very damaging. This is why these drugs are not prescribed for long-term use.
  • Common side effects of hydrocortisone include diarrhea, nausea, difficulty in sleeping, sweating, and restlessness. Furthermore, these type of drugs generate few serious side effects such as muscle pain, signs of a severe allergic reaction, severe vomiting, and seizures.
  • Various side effects associated with the use of hydrocortisone may hamper the market growth

Hydrocortisone Market: Competition Landscape

  • This report profiles major players in the global hydrocortisone market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global hydrocortisone market is highly fragmented, with the presence of many multinational and small regional players in the market
  • The major players operating in the global hydrocortisone market are 
    • Pfizer, Inc.
    • Novartis AG
    • Mylan N.V.,
    • Hikma Pharmaceuticals Plc
    • GlaxoSmithKline plc,
    • Cipla Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Abbott Laboratories
    • Bayer AG

Hydrocortisone Market: Key Developments

  • In July 2019, Mylan and Upjohn (a division of Pfizer) entered into a definitive agreement to combine Mylan with Upjohn, to create a new global pharmaceutical company
  • The report on the global hydrocortisone market discussed individual strategies, followed by company profile of manufacturer of hydrocortisone. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global hydrocortisone market.

Hydrocortisone Market - Segmentation

Indication

Adrenocortical Insufficiency

Adrenergic Syndrome

High Blood Calcium

Thyroiditis

Rheumatoid Arthritis

Dermatitis

Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Others

Route of Administration

Parenteral

Oral

Topical

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

The global hydrocortisone market was worth US$ 1 Bn and is projected to reach a value of US$ 2 Bn by the end of 2028

Hydrocortisone market is anticipated to grow at a CAGR of 4% during the forecast period

North America accounted for a major share of the global hydrocortisone market

Hydrocortisone market is driven by rise in cases of adrenocortical insufficiency and increase in investment in research & development are projected to drive the global market during the forecast period

Key players in the global hydrocortisone market include Pfizer, Inc., Novartis AG, Mylan N.V., Hikma Pharmaceuticals Plc, GlaxoSmithKline plc, Cipla Inc., Sun Pharmaceutical Industries Ltd., Abbott Laboratories, and Bayer AG

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Hydrocortisone Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Hydrocortisone Market Analysis and Forecast, 2018–2028

5. Key Insights

    5.1. Regulatory Scenario, by Region/globally

6. Global Hydrocortisone Market Analysis and Forecast, by  Indication 

    6.1. Introduction 

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by  Indication, 2018–2028

        6.3.1. Adrenocortical Insufficiency

        6.3.2. Adrenergic Syndrome

        6.3.3. High Blood Calcium

        6.3.4. Thyroiditis

        6.3.5. Rheumatoid Arthritis

        6.3.6. Dermatitis

        6.3.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)

        6.3.8. Others

    6.4. Market Attractiveness, by Indication 

7. Global Hydrocortisone Market Analysis and Forecast, by  Route of Administration 

    7.1. Introduction 

    7.2. Key Findings / Developments

    7.3. Market Value  Forecast, by Route of Administration, 2018–2028

        7.3.1. Parenteral

        7.3.2. Oral

        7.3.3. Topical

        7.3.4. Rectal

    7.4. Market Attractiveness, by Route of Administration 

8. Global Hydrocortisone Market Analysis and Forecast, by  Distribution Channel 

    8.1. Introduction 

    8.2. Key Findings / Developments

    8.3. Market Value  Forecast, by  Distribution Channel, 2018–2028

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness, by Distribution Channel 

9. Global Hydrocortisone Market Analysis and Forecast, by  Region

    9.1. Key Findings

    9.2. Market Value  Forecast, by  Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Market Attractiveness, by Region

10. North America Hydrocortisone Market Analysis and Forecast

    10.1. Introduction

    10.2. Market Value  Forecast, by  Indication, 2018–2028

        10.2.1. Adrenocortical Insufficiency

        10.2.2. Adrenergic Syndrome

        10.2.3. High Blood Calcium

        10.2.4. Thyroiditis

        10.2.5. Rheumatoid Arthritis

        10.2.6. Dermatitis

        10.2.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)

        10.2.8. Others

    10.3. Market Value  Forecast, by  Route of Administration, 2018–2028

        10.3.1. Parenteral

        10.3.2. Oral

        10.3.3. Topical

        10.3.4. Rectal

    10.4. Market Value  Forecast, by  Distribution Channel, 2018–2028

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. Market Value  Forecast, by  Country, 2018–2028

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis 

        10.6.1. By Indication 

        10.6.2. By Route of Administration 

        10.6.3. By Distribution Channel 

        10.6.4. By Country

11. Europe Hydrocortisone Market Analysis and Forecast

    11.1. Introduction

    11.2. Market Value  Forecast, by  Indication, 2018–2028

        11.2.1. Adrenocortical Insufficiency

        11.2.2. Adrenergic Syndrome

        11.2.3. High Blood Calcium

        11.2.4. Thyroiditis

        11.2.5. Rheumatoid Arthritis

        11.2.6. Dermatitis

        11.2.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)

        11.2.8. Others

    11.3. Market Value  Forecast, by  Route of Administration, 2018–2028

        11.3.1. Parenteral

        11.3.2. Oral

        11.3.3. Topical

        11.3.4. Rectal

    11.4. Market Value  Forecast, by  Distribution Channel, 2018–2028

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value  Forecast, by  Country/Sub-region, 2018–2028

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis 

        11.6.1. By Indication 

        11.6.2. By Route of Administration 

        11.6.3. By Distribution Channel 

        11.6.4. By Country/Sub-region

12. Asia Pacific Hydrocortisone Market Analysis and Forecast

    12.1. Introduction

    12.2. Market Value  Forecast, by  Indication, 2018–2028

        12.2.1. Adrenocortical Insufficiency

        12.2.2. Adrenergic Syndrome

        12.2.3. High Blood Calcium

        12.2.4. Thyroiditis

        12.2.5. Rheumatoid Arthritis

        12.2.6. Dermatitis

        12.2.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)

        12.2.8. Others

    12.3. Market Value  Forecast, by  Route of Administration, 2018–2028

        12.3.1. Parenteral

        12.3.2. Oral

        12.3.3. Topical

        12.3.4. Rectal

    12.4. Market Value  Forecast, by  Distribution Channel, 2018–2028

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value  Forecast, by  Country/Sub-region, 2018–2028

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis 

        12.6.1. By Indication 

        12.6.2. By Route of Administration 

        12.6.3. By Distribution Channel 

        12.6.4. By Country/Sub-region

13. Latin America Hydrocortisone Market Analysis and Forecast

    13.1. Introduction

    13.2. Market Value  Forecast, by  Indication, 2018–2028

        13.2.1. Adrenocortical Insufficiency

        13.2.2. Adrenergic Syndrome

        13.2.3. High Blood Calcium

        13.2.4. Thyroiditis

        13.2.5. Rheumatoid Arthritis

        13.2.6. Dermatitis

        13.2.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)

        13.2.8. Others

    13.3. Market Value  Forecast, by  Route of Administration, 2018–2028

        13.3.1. Parenteral

        13.3.2. Oral

        13.3.3. Topical

        13.3.4. Rectal

    13.4. Market Value  Forecast, by  Distribution Channel, 2018–2028

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value  Forecast, by  Country/Sub-region, 2018–2028

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis 

        13.6.1. By Indication 

        13.6.2. By Route of Administration 

        13.6.3. By Distribution Channel 

        13.6.4. By Country/Sub-region

14. Middle East & Africa Hydrocortisone Market Analysis and Forecast

    14.1. Introduction

    14.2. Market Value  Forecast, by  Indication, 2018–2028

        14.2.1. Adrenocortical Insufficiency

        14.2.2. Adrenergic Syndrome

        14.2.3. High Blood Calcium

        14.2.4. Thyroiditis

        14.2.5. Rheumatoid Arthritis

        14.2.6. Dermatitis

        14.2.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)

        14.2.8. Others

    14.3. Market Value  Forecast, by  Route of Administration, 2018–2028

        14.3.1. Parenteral

        14.3.2. Oral

        14.3.3. Topical

        14.3.4. Rectal

    14.4. Market Value  Forecast, by  Distribution Channel, 2018–2028

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value  Forecast, by  Country/Sub-region, 2018–2028

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis 

        14.6.1. By Indication 

        14.6.2. By Route of Administration 

        14.6.3. By Distribution Channel 

        14.6.4. By Country/Sub-region

15. Company Profiles

    15.1. Pfizer, Inc.

            15.1.1.1. Company Overview

            15.1.1.2. Company Financials

            15.1.1.3. Growth Strategies

            15.1.1.4. SWOT Analysis

    15.2. Novartis AG

            15.2.1.1. Company Overview

            15.2.1.2. Company Financials

            15.2.1.3. Growth Strategies

            15.2.1.4. SWOT Analysis 

    15.3. Mylan N.V.

            15.3.1.1. Company Overview

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

    15.4. Hikma Pharmaceuticals Plc

            15.4.1.1. Company Overview

            15.4.1.2. Company Financials

            15.4.1.3. Growth Strategies

            15.4.1.4. SWOT Analysis

    15.5. GlaxoSmithKline plc

            15.5.1.1. Company Overview

            15.5.1.2. Company Financials

            15.5.1.3. Growth Strategies

            15.5.1.4. SWOT Analysis

    15.6. Cipla Inc.

            15.6.1.1. Company Overview

            15.6.1.2. Company Financials

            15.6.1.3. Growth Strategies

            15.6.1.4. SWOT Analysis

    15.7. Sun Pharmaceutical Industries Ltd.

            15.7.1.1. Company Overview

            15.7.1.2. Company Financials

            15.7.1.3. Growth Strategies

            15.7.1.4. SWOT Analysis

    15.8. Abbott Laboratories

            15.8.1.1. Company Overview

            15.8.1.2. Company Financials

            15.8.1.3. Growth Strategies

            15.8.1.4. SWOT Analysis

    15.9. Bayer AG 

            15.9.1.1. Company Overview

            15.9.1.2. Company Financials

            15.9.1.3. Growth Strategies

            15.9.1.4. SWOT Analysis

List of Tables

Table 01: Comparison of Regulatory Requirements for Generic Drugs Dossier Submission in the U.S. and Canada

Table 02: Global Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028

Table 03: Global Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028

Table 04: Global Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 05: Global Hydrocortisone Market Value (US$ Mn) Forecast, by Region, 2018–2028

Table 06: North America Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028

Table 07: North America Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028

Table 08: North America Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 09: North America Hydrocortisone Market Value (US$ Mn) Forecast, by Country, 2018–2028

Table 10: Europe Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028

Table 11: Europe Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028

Table 12: Europe Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 13: Europe Hydrocortisone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

Table 14: Asia Pacific Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028

Table 15: Asia Pacific Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028

Table 16: Asia Pacific Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 17: Asia Pacific Hydrocortisone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

Table 18: Latin America Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028

Table 19: Latin America Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028

Table 20: Latin America Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 21: Latin America Hydrocortisone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

Table 22: Middle East & Africa Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028

Table 23: Middle East & Africa Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028

Table 24: Middle East & Africa Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 25: Middle East & Africa Hydrocortisone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

List of Figures

Figure 01: Global Hydrocortisone Market Snapshot 

Figure 02: Global Hydrocortisone Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2028

Figure 03: Global Hydrocortisone Market Value (US$ Mn) Forecast, 2018–2028

Figure 04: Regulatory Approval Process - The U.S.  

Figure 05: Regulatory Approval Process - Europe 

Figure 06: Regulatory Approval Process - Japan

Figure 07: Drug Development

Figure 08: Global Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028

Figure 09: Global Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028

Figure 10: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Adrenocortical Insufficiency, 2018–2028

Figure 11: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Adrenogenital Disorder, 2018–2028

Figure 12: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by High Blood Calcium, 2018–2028

Figure 13: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Thyroiditis, 2018–2028

Figure 14: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Rheumatoid Arthritis, 2018–2028

Figure 15: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Dermatitis, 2018–2028

Figure 16: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Asthma and Chronic Obstructive Pulmonary Disease (COPD), 2018–2028

Figure 17: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2028

Figure 18: Global Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028

Figure 19: Global Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028

Figure 20: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth, by Parenteral, 2018–2028

Figure 21: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth, by Oral, 2018–2028

Figure 22: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth, by Topical, 2018–2028

Figure 23: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth, by Rectal, 2018–2028

Figure 24: Global Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028

Figure 25: Global Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028

Figure 26: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2018–2028

Figure 27: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2018–2028

Figure 28: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth, by Online Pharmacies, 2018–2028

Figure 29: Global Hydrocortisone Market Value Share Analysis, by Region, 2019 and 2028

Figure 30: Global Hydrocortisone Market Attractiveness Analysis, by Region, 2020–2028

Figure 31: North America Hydrocortisone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2028

Figure 32: North America Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028

Figure 33: North America Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028

Figure 34: North America Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028

Figure 35: North America Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028

Figure 36: North America Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028

Figure 37: North America Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028

Figure 38: North America Hydrocortisone Market Value Share Analysis, by Country, 2019 and 2028

Figure 39: North America Hydrocortisone Market Attractiveness Analysis, by Country, 2020–2028

Figure 40: Europe Hydrocortisone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2028

Figure 41: Europe Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028

Figure 42: Europe Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028

Figure 43: Europe Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028

Figure 44: Europe Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028

Figure 45: Europe Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028

Figure 46: Europe Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028

Figure 47: Europe Hydrocortisone Market Value Share Analysis, by Country/Sub-region, 2019 and 2028

Figure 48: Europe Hydrocortisone Market Attractiveness Analysis, by Country/Sub-region, 2020–2028

Figure 49: Asia Pacific Hydrocortisone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2028

Figure 50: Asia Pacific Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028

Figure 51: Asia Pacific Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028

Figure 52: Asia Pacific Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028

Figure 53: Asia Pacific Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028

Figure 54: Asia Pacific Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028

Figure 55: Asia Pacific Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028

Figure 56: Asia Pacific Hydrocortisone Market Value Share Analysis, by Country/Sub-region, 2019 and 2028

Figure 57: Asia Pacific Hydrocortisone Market Attractiveness Analysis, by Country/Sub-region, 2020–2028

Figure 58: Latin America Hydrocortisone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2028

Figure 59: Latin America Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028

Figure 60: Latin America Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028

Figure 61: Latin America Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028

Figure 62: Latin America Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028

Figure 63: Latin America Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028

Figure 64: Latin America Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028

Figure 65: Latin America Hydrocortisone Market Value Share Analysis, by Country/Sub-region, 2019 and 2028

Figure 66: Latin America Hydrocortisone Market Attractiveness Analysis, by Country/Sub-region, 2020–2028

Figure 67: Middle East & Africa Hydrocortisone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2028

Figure 68: Middle East & Africa Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028

Figure 69: Middle East & Africa Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028

Figure 70: Middle East & Africa Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028

Figure 71: Middle East & Africa Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028

Figure 72: Middle East & Africa Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028

Figure 73: Middle East & Africa Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028

Figure 74: Middle East & Africa Hydrocortisone Market Value Share Analysis, by Country/Sub-region, 2019 and 2028

Figure 75: Middle East & Africa Hydrocortisone Market Attractiveness Analysis, by Country/Sub-region, 2020–2028

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Hydrocortisone Market